Point of Care Diagnostics/Testing Market Size, Share & Trends Analysis Report by Product (Glucose, Blood Gas/Electrolytes, Cancer Marker), By End Use (Clinic, Hospital), And Segment Forecasts, 2019 - 2025

Industry Insights

The global point of care diagnostics/testing market was valued at USD 18.09 billion in 2018 and is expected to register a CAGR of 3.3% over the forecast period. Continuous developments in R&D activities to miniaturize molecular and professional diagnostic tests is anticipated to drive the demand for the devices. In addition, improvements in lab automation techniques coupled with introduction of cost-effective and high-quality medical solutions is set to propel the growth.

Emergence of Electronic Medical Records (EMR) usage with Point of Care (POC) diagnostics has improved patient care. EMR facilitates transmission of test results from POC devices to laboratory or hospital information system, minimizing the workload and discrepancies in health data. 

Additionally, patients and clinicians are more inclined towards the usage of POC diagnostic tests with increasing levels of patient awareness about the POC processes drives the market. Also, minimally skilled professionals efficiently use POC devices for diagnosis, which serves as one of the market drivers.

Increasing prevalence of chronic disorders coupled with rise in geriatric population increases the customer base who are more prone to disease development drives the market expansion. According to the International Diabetes Federation, approximately 425 million adults globally had diabetes in 2017-18 and it is expected to escalate up to 629 million cases by 2045. POC glucose meters have proved to be significantly useful in managing glycemic levels in diabetic patients.

Other factors driving the POC diagnostics/testing market growth include rising investment by multiple public foundations. As reported on November 2018, the Massachusetts Medical Device Development Center established a center with the support of USD 7.9 million grant from the National Institute of Health (NIH). This center focuses on assisting investors who are dealing with point-of-care products and technologies.

Several private entities such as Dartmouth College, California Institute of Technology, and global organizations are also involved in POC development programs. For instance, in August 2018, the American Association for Clinical Chemistry released certification program for POC testing professionals, to improve their diagnostic testing outside the clinical laboratories.

Product Insights

Glucose testing led the market in 2018 due to an improved commercialization rate of portable glucose meters in past few years. Patients are aware of the fact that monitoring of glucose level at regular intervals is essential for diabetic patients. This has spurred the employment of hand-held glucose meters in home care settings.

High prevalence of diabetes across the world is projected to drive the demand these tests. In addition, implementation of glucose biosensors also translates these tests to be used in several healthcare centers where they support the clinicians to monitor disease progression with lesser complications.

However, this segment is relatively more saturated as compared to other products and is anticipated to witness slower CAGR over the forecast period. On the other hand, cancer markers based POC testing segment is likely to register lucrative pace throughout the forecast period.

The major factor fostering its growth is ongoing R&D activities due to increasing cancer prevalence. The advent of cancer detection by monitoring and analyzing circulating tumor cells has improved the cancer research and diagnosis. Moreover, launch of several home-testing cancer kits is expected to drive the segment growth in various healthcare settings.

End Use Insights

Clinics segment captured the largest market share in terms of revenue in 2018. A significant number of Clinical Laboratory Improvement Amendments (CLIA)-waived tests are implemented within clinics for diagnosis of a diverse range of disorders. Besides, availability ofseveral portable POC devices outside the hospital setting drives the POC diagnostics in clinics.

Decentralization of primary care services in various regional markets and initiatives by government agencies, such as National Health Service augment the segment growth. In February 2018, the National Science Foundation awarded USD 10.0 million to the Houston’s Rice University for the development of a POC solution named mHealth device. 

However, home-based POC testing is expected to emerge as the fast growing segment during the forecast period. Introduction of economical and portable POC products for early detection and prevention of diseases boost the demand of home POC testing segment. Moreover, emergence of POC in home settings also maintain comfort level of patients.

Regional Insights

North America accounted for the highest market share in 2018 due to the high awareness accompanied by high disease prevalence. Favorable government regulations and initiatives pertaining to development of healthcare infrastructure also support for the large share of this region.

Numerous product launches and strategic developments by key players in U.S. are also anticipated to drive the regional market. For instance, in November 2018, PixCell Medical received the Food and Drug Administration (FDA) approval for its point of care HemoScreen Hematology Analyzer. Likewise, in October 2017, Abbott Laboratories acquired Alere Inc. that strengthened the POC testing offerings of Abbott.

On the other hand, Asia Pacific is projected to be the most attractive regional segment. This is majorly due to strategic initiatives adopted by international players to improve healthcare infrastructure. Growing awareness and presence of a huge patient pool in developing economies such as India and China can further fuel the regional demand.

For instance, in April 2017, the U.S. based POC diagnostic test provider, Chembio Diagnostics, Inc., collaborated with FIND to identify life-threatening disorders in the Asia Pacific region. Together, they detected multiple diseases by using Chembio’s DPP technology platform. Such programs led to expansion of innovative POC diagnostic tests especially in developing nations.

Point of Care Diagnostics/Testing Market Share Insights

The key players operating in the market include F. Hoffmann-La Roche Ltd.; Danaher Corporation; Abbott Laboratories; bioMérieux SA; Instrumentation Laboratory SpA; Nova Biomedical; Trividia Health, Inc.; QIAGEN; Becton Dickinson & Company; Sekisui Diagnostics LLC; Quidel Corporation; and Siemens Healthcare GmbH.

Key participants engage in commercialization their products through the medical equipment distributors that operate in several regional markets. These are also involved in developmentof more sophisticated bench top testing products, accounting for significant competition with respect to the distribution network and market presence.

Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country level and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2014 to 2025. For the purpose of this report, Grand View Research has segmented the global point of care diagnostics/testing market report on the basis of product, end use, and region:

• Product Outlook (Revenue, USD Million, 2014 - 2025)

  • Glucose Testing

  • Hb1Ac Testing

  • Coagulation

  • Fertility

  • Infectious Diseases

    • HIV POC

    • Clostridium Difficile POC

    • HBV POC

    • Pneumonia or Streptococcus Associated Infections

    • Respiratory Syncytial Virus (RSV) POC

    • HPV POC

    • Influenza/Flu POC

    • HCV POC

    • MRSA POC

    • TB and Drug-Resistant TB POC

    • HSV POC

    • Other Infectious Diseases

  • Cardiac Markers

  • Thyroid Stimulating Hormone

  • Hematology

  • Primary Care Systems

  • Decentralized Clinical Chemistry

  • Feces

  • Lipid Testing

  • Cancer Marker

  • Blood Gas/Electrolytes

  • Ambulatory Chemistry

  • Drug Abuse Testing

  • Urinalysis

• End Use Outlook (Revenue, USD Million, 2014 - 2025)

  • Clinics

    • Physician Office

    • Pharmacy & Retail Clinics

    • Non-practice Clinics

    • Urgent Care Clinic

  • Hospitals

  • Home

  • Assisted Living Healthcare Facilities

  • Laboratory

• Regional Outlook (Revenue, USD Million, 2014 - 2025)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • France

    • U.K.

    • Italy

    • Spain

  • Asia Pacific

    • China

    • Japan

    • India

    • Korea

    • Australia

    • Singapore

  • Latin America

    • Brazil

    • Mexico

    • Chile

    • Argentina

  • Middle East & Africa

    • Saudi Arabia

    • South Africa

    • United Arab Emirates

    • Nigeria

    • Qatar

    • Kenya

    • Zimbabwe